News headlines about Supernus Pharmaceuticals (NASDAQ:SUPN) have been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Supernus Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 46.5227310931129 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
- Insider Selling: Supernus Pharmaceuticals Inc (SUPN) VP Sells 5,750 Shares of Stock (americanbankingnews.com)
- Supernus Pharmaceuticals (SUPN) Raised to “Strong-Buy” at BidaskClub (americanbankingnews.com)
- Supernus Pharma (SUPN) Announces Passing of Board Member William Nuerge on January 10, 2018 – StreetInsider.com (streetinsider.com)
- Supernus Pharmaceuticals (SUPN) Downgraded by Zacks Investment Research to “Hold” (americanbankingnews.com)
- Insider Selling: Supernus Pharmaceuticals Inc (SUPN) CFO Sells 50,000 Shares of Stock (americanbankingnews.com)
Shares of Supernus Pharmaceuticals (SUPN) opened at $42.75 on Wednesday. The company has a market cap of $2,190.00, a PE ratio of 38.86 and a beta of 1.17. Supernus Pharmaceuticals has a 1 year low of $23.10 and a 1 year high of $50.04.
SUPN has been the topic of several recent research reports. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. FBR & Co initiated coverage on shares of Supernus Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $53.00 target price on the stock. Janney Montgomery Scott upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Monday, December 4th. Stifel Nicolaus raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research report on Tuesday, November 7th. Finally, Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 23rd. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $49.90.
In related news, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total value of $2,178,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Victor Vaughn sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $42.04, for a total transaction of $630,600.00. Following the completion of the transaction, the vice president now directly owns 24,344 shares of the company’s stock, valued at $1,023,421.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 125,750 shares of company stock valued at $5,273,573. Insiders own 6.70% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.